论文部分内容阅读
目的:观察胰岛素增敏剂吡格列酮对糖尿病大鼠肾小球肝素酶的表达,探讨其肾脏的保护作用及其机制。方法:将雌性SD大鼠分为3组:正常对照组(NC,n=10)、糖尿病组(DM,n=12)和吡格列酮组(DP,n=12)。链脲菌素腹腔注射诱导糖尿病大鼠模型。实验第6周,测定血糖(BG)、糖化血红蛋白(GHb),血尿素氮(BUN)、血肌酐(Scr),24 h尿蛋白(24 h UP)、尿足细胞(UPC)排泄水平。RT-PCR检测肾小球肝素酶mRNA的表达,肾小球间接免疫荧光分析肝素酶的表达分布。结果:与DM组相比,DP组BG、GHb、BUN、Scr水平显著降低(P<0.01);24 h UP、UPC排泄量亦明显减少(P<0.05);肝素酶mRNA的表达及平均吸光度值显著降低(P<0.05)。结论:吡格列酮可抑制肝素酶的表达,减轻蛋白尿,对糖尿病肾脏病变有保护作用。
Objective: To observe the effect of insulin sensitizer pioglitazone on the expression of glomerular heparanase in diabetic rats and to explore the protective effect and mechanism of it on kidneys. Methods: Female SD rats were divided into 3 groups: normal control group (NC, n = 10), diabetic group (DM, n = 12) and pioglitazone group (DP, n = 12). Induction of diabetic rat model by intraperitoneal injection of streptozotocin. The levels of blood glucose (BG), glycosylated hemoglobin (GHb), blood urea nitrogen (BUN), serum creatinine (Scr), 24h urinary protein (24 h UP) and urinary podocyte (UPC) The expression of glomerular heparanase mRNA was detected by RT-PCR and the expression of heparanase was analyzed by indirect immunofluorescence. Results: Compared with DM group, the levels of BG, GHb, BUN and Scr in DP group were significantly decreased (P <0.01), and the levels of UP and UPC in 24 h group were significantly decreased (P <0.05) Absorbance values were significantly lower (P <0.05). Conclusion: Pioglitazone can inhibit the expression of heparanase and reduce proteinuria, which has a protective effect on diabetic nephropathy.